Generative artificial intelligence promises to revolutionize healthcare, influencing areas like drug development and expediting diagnoses. However, the World Health Organization (WHO) issued a cautionary note on Thursday, emphasizing the need for heightened attention to associated risks.
Exploring AI Large Multi-Modal Models (LMMs) in Healthcare
The WHO has been actively evaluating the potential benefits and risks posed by AI Large Multi-Modal Models (LMMs), a relatively recent development rapidly gaining prominence in the healthcare sector. LMMs represent a form of generative AI capable of utilizing diverse data inputs, including text, images, and video, to generate outputs not restricted to the type of data fed into the algorithm.
According to the Manila Bulletin, LMMs are anticipated to find extensive applications in healthcare, scientific research, public health, and drug development. The organization outlined five key areas where this technology could be deployed: diagnosis, scientific research and drug development, medical and nursing education, clerical tasks, and patient-guided use for investigating symptoms.
Balancing Potential With Recognized Risks
While acknowledging the potential benefits, the WHO cautioned against documented risks associated with LMMs. These risks include the potential for generating false, inaccurate, biased, or incomplete outcomes.
The WHO highlighted the inevitability of errors, misuse, and potential harm to individuals as LMMs gain broader usage in healthcare. To address these concerns, the organization issued recommendations on the ethics and governance of LMMs to guide governments, tech firms, and healthcare providers in safely leveraging this technology.
According to WHO, Chief Scientist Jeremy Farrar emphasized the potential of generative AI technologies to improve healthcare but stressed the crucial need for identifying and fully addressing associated risks. The guidance called for collaborative development involving scientists, engineers, medical professionals, and patients.
Additionally, the WHO underscored the vulnerability of LMMs to cybersecurity risks, emphasizing the necessity for regulatory approval, auditing, and impact assessments in healthcare settings. As generative AI continues to evolve, vigilance and ethical considerations remain paramount for its responsible integration into healthcare practices.
Photo: Scott Graham/Unsplash


Google Cloud and Liberty Global Forge Strategic AI Partnership to Transform European Telecom Services
Pentagon and Anthropic Clash Over AI Safeguards in National Security Use
SoftBank and Intel Partner to Develop Next-Generation Memory Chips for AI Data Centers
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies
Nvidia’s $100 Billion OpenAI Investment Faces Internal Doubts, Report Says
Meta Stock Surges After Q4 2025 Earnings Beat and Strong Q1 2026 Revenue Outlook Despite Higher Capex
Nvidia Confirms Major OpenAI Investment Amid AI Funding Race
US Judge Rejects $2.36B Penalty Bid Against Google in Privacy Data Case
Sam Altman Reaffirms OpenAI’s Long-Term Commitment to NVIDIA Amid Chip Report
Jensen Huang Urges Taiwan Suppliers to Boost AI Chip Production Amid Surging Demand
Apple Earnings Beat Expectations as iPhone Sales Surge to Four-Year High
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns
Palantir Stock Jumps After Strong Q4 Earnings Beat and Upbeat 2026 Revenue Forecast
Elon Musk’s Empire: SpaceX, Tesla, and xAI Merger Talks Spark Investor Debate
Amazon Stock Dips as Reports Link Company to Potential $50B OpenAI Investment
Federal Judge Signals Possible Dismissal of xAI Lawsuit Against OpenAI 



